Repertoire® Immune Medicines Announces Strategic Collaboration with Lilly to Develop Tolerizing Therapies for Autoimmune Diseases
News 01.02.2026 CAMBRIDGE, Mass. – January 29, 2026 – Repertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell targeted immune medicines, announced today that it has entered a strategic collaboration with Eli Lilly and Company (“Lilly”) to develop tolerizing therapies for multiple autoimmune diseases. The collaboration...